IDEXX Laboratories/$IDXX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About IDEXX Laboratories
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
Ticker
$IDXX
Sector
Primary listing
Industry
Health Care Equipment and Supplies
Headquarters
Employees
11,000
ISIN
US45168D1046
Website
IDXX Metrics
BasicAdvanced
$42B
47.96
$10.82
1.52
-
Price and volume
Market cap
$42B
Beta
1.52
52-week high
$549.52
52-week low
$356.14
Average daily volume
448K
Financial strength
Current ratio
1.16
Quick ratio
0.609
Long term debt to equity
37.762
Total debt to equity
64.932
Interest coverage (TTM)
34.12%
Profitability
EBITDA (TTM)
1,341.508
Gross margin (TTM)
61.28%
Net profit margin (TTM)
22.76%
Operating margin (TTM)
30.71%
Effective tax rate (TTM)
20.41%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
22.98%
Return on equity (TTM)
59.33%
Valuation
Price to earnings (TTM)
47.962
Price to revenue (TTM)
10.821
Price to book
28.92
Price to tangible book (TTM)
44.88
Price to free cash flow (TTM)
50.789
Free cash flow yield (TTM)
1.97%
Free cash flow per share (TTM)
1,021.31%
Growth
Revenue change (TTM)
5.56%
Earnings per share change (TTM)
4.80%
3-year revenue growth (CAGR)
6.29%
10-year revenue growth (CAGR)
10.06%
3-year earnings per share growth (CAGR)
8.29%
10-year earnings per share growth (CAGR)
19.42%
What the Analysts think about IDXX
Analyst ratings (Buy, Hold, Sell) for IDEXX Laboratories stock.
Bulls say / Bears say
IDEXX Laboratories raised its annual profit forecast, now projecting earnings between $11.93 and $12.43 per share, up from the previous range of $11.74 to $12.24, indicating strong demand for its pet diagnostics. (reuters.com)
The company reported a 7% year-over-year increase in total quarterly revenues, reaching $976 million, with its companion animal group unit sales rising about 6% to $892 million, showcasing robust growth in its core segment. (reuters.com)
IDEXX Laboratories' stock reached a 52-week high of $546.61, reflecting strong investor confidence and positive market momentum. (investing.com)
IDEXX Laboratories lowered its annual revenue forecast for the third time, now expecting full-year revenue between $3.87 billion and $3.89 billion, down $38 million from previous predictions, due to a decrease in veterinary clinic visits amid inflationary pressures and staffing challenges. (reuters.com)
The company faces challenges in the Asia-Pacific region, including reduced swine testing in China and lower health screening revenues, which have restricted the overall organic growth of its Livestock, Poultry, and Dairy business. (nasdaq.com)
Global macroeconomic conditions, including supply chain disruptions and fluctuations in foreign currency exchange rates, have negatively impacted IDEXX's revenues from international transactions, with the strengthening of the U.S. dollar affecting its financial performance. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
IDXX Financial Performance
Revenues and expenses
IDXX Earnings Performance
Company profitability
IDXX News
AllArticlesVideos
IDEXX Laboratories to Release 2025 Second Quarter Financial Results
Business Wire·3 weeks ago
IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day
Business Wire·2 months ago
IDEXX Laboratories raises annual profit view on strong demand for its pet diagnostics
Reuters·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for IDEXX Laboratories stock?
IDEXX Laboratories (IDXX) has a market cap of $42B as of July 18, 2025.
What is the P/E ratio for IDEXX Laboratories stock?
The price to earnings (P/E) ratio for IDEXX Laboratories (IDXX) stock is 47.96 as of July 18, 2025.
Does IDEXX Laboratories stock pay dividends?
No, IDEXX Laboratories (IDXX) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next IDEXX Laboratories dividend payment date?
IDEXX Laboratories (IDXX) stock does not pay dividends to its shareholders.
What is the beta indicator for IDEXX Laboratories?
IDEXX Laboratories (IDXX) has a beta rating of 1.52. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.